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The present trial aimed to investigate the effects of pioglitazone on the serum level of asymmetric dimethylarginine (ADMA),
a marker of endothelial function, and some indices of inflammation and glucose and lipid metabolism in nondiabetic metabolic
syndrome patients. 104 eligible participants (57% female; age between 20 and 70)were enrolled in a double-blind placebo-controlled
trial and were randomized to receive either pioglitazone (uptitrated to 30mg/day) or matching placebo for 24weeks. Participants
were clinically examined and a blood sample was obtained at baseline and at the end of the trial. Pioglitazone significantly
improved C-reactive protein level irrespective of changes in insulin sensitivity. Compared with the placebo group, alanine and
aspartate transaminases were decreased and high-density lipoprotein cholesterol was increased after treatment with pioglitazone. A
considerably greater weight gain was also recorded in the intervention group.We failed to observe any significant changes in serum
ADMA in either group and between groups with and without adjustment for age, sex, and components of the metabolic syndrome.
In a nutshell, pioglitazone seems to have positive effects on lipid profile, liver transaminases, and systemic inflammation. However,
its previously demonstrated endothelial function-improving properties do not seem to be mediated by ADMA.
1. Introduction
Metabolic syndrome (MetS) is widely accepted as a concept
which encompasses a cluster of cardiovascular risk factors.
Although some authors have claimed against the additional
value of the syndrome over its component parts in identifying
cardiometabolic risk [1], it has been demonstrated that
affected individuals are at two-to-three-fold higher risk of
developing coronary heart disease and a fivefold increased
risk of type-2 diabetes mellitus (T2DM) [2, 3]. Insulin resis-
tance (IR), a key contributingmechanism to the development
of the syndrome, is turned out to be associated with endothe-
lial dysfunction (ED) [4]. In turn, ED is correlated with all
risk factors of atherosclerosis [5].
ED is generally defined as the impairment of end-
othelium-dependent vasodilatation secondary to reduced
bioavailability of nitric oxide (NO) [6]. NO production is cat-
alyzed by the nitric oxide synthase (NOS) family of enzymes
[7]. It has been shown that insulin induces endothelium-
dependent vasodilatation via activating endothelial NOS [8].
Decreased bioavailability of NO mediated by endogenous
inhibitors of NOS would diminish delivery of insulin and
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glucose to metabolically active tissues and, consequently,
further aggravate the underlying IR in form of a vicious cycle
[9].
Pioglitazone, a member of thiazolidinedione (TZD) fam-
ily of drugs, is potent synthetic ligand for peroxisome
proliferator-activated receptor gamma (PPAR-𝛾). The vas-
cular and metabolic effects of TZDs on nondiabetic MetS
patients have been the subject of a number of investiga-
tions during the recent years [10–14]. Up-to-date, molecu-
lar mediators of the ameliorating effect of pioglitazone on
endothelium-dependent vasodilatation assessed by arterial
flow-mediated vasodilation [10, 13–15] and venous occlusion
plethysmography [16] have not thoroughly been studied.
However, asymmetric dimethylarginine (ADMA), the prin-
cipal endogenous NOS inhibitor, has been proposed as a
possible option. Previous investigations have shown elevated
levels of ADMA in non-diabetic insulin resistant subjects [17]
and MetS patients [18]. This factor contradicts the vascular
effects of insulin and contributes to vascular insulin resistance
[19] and ED [20]. Furthermore, there is strong evidence
showing that ADMA is independently correlated with total
and vascular mortality [21, 22]. More significantly, it is
propounded not only as a marker of disease but also as a
player, and a target of pharmacologic therapy [23]. Limited
available animal [24, 25] and clinical [14, 15, 17, 26] studies
which evaluated the effects of TZDs on ADMA levels have
produced contradictory outcomes.
This paper is presenting a part of the EPICAMP: effects
of pioglitazone on cardiac structure, markers of endothelial
function andpsychological status study, a trial aimed to inves-
tigate the efficacy of pioglitazone monotherapy in improving
a number of cardiovascular and psychiatric indices in a group
of non-diabetic MetS patients. This part was designed to
assess the influence of pioglitazone on the serum level of
ADMA, systemic inflammation, and some indices of glucose
and lipid metabolism.
2. Materials and Methods
2.1. Study Design. Eligible volunteers were enrolled in
a double-blind placebo-controlled trial and were equally
randomized to receive either pioglitazone (uptitrated to
30mg/day) or matching placebo for 24 weeks. A random
number list generated by random-list generator software was
used in allocation of the participants. In order to observe
double-blindness, the personnel who randomized patients,
had no role in the data collection. For more confidentiality,
we used patients’ codes at all follow-up phases. Pioglitazone
and identical placebo tablets were provided by Osvah Phar-
maceutical Company (Tehran, Iran).
The study protocol was reviewed and approved by the
Isfahan Cardiovascular Research Institute ethics committee,
affiliated to Isfahan University of Medical Sciences as well as
the ethics committee ofAJAUniversity ofMedical Sciences. A
written informed consent was also obtained from all patients
after providing a brief explanation of the study method and
goals.The present study was registered in the Australian New
Zealand clinical trials registry (http://www.anzctr.org.au/,
identifier: ACTRN12611000351910) and Iranian registry of
clinical trials (http://www.irct.ir/, identifier: IRCT201101023
733N2). None of the volunteers were paid for participation in
the study.
2.2. Study Population. Study population was randomly
selected among MetS patients who participated in the first
phase of Isfahan Healthy Heart Program (IHHP). Details
of IHHP are described elsewhere [27]. Recruitment took
place in the Isfahan Cardiovascular Research Institute from
March to May of 2011. Selected patients underwent screening
laboratory tests as well as physical examination and struc-
tured interview by a physician. Being nondiabetic and having
metabolic syndrome were our main eligibility criteria. MetS
was defined following the harmonized criteria using the
indices of obesity for Middle Easterns [28]. The diagnosis
of T2DM was made based on the criteria provided by the
American Diabetes Association [29].
Major exclusion criteria were as follows: New York
Heart Association functional class 3 or 4, any history or
evidences of ischemic heart disease, having polycystic ovary
syndrome, impaired liver function (ALT > 2.5 times of upper
limit of normal), renal dysfunction with serum creatinine
>1.5mg/dL, any debilitating medical condition, participation
in a weight reduction program, being under treatment with
metformin or a TZD within the preceding three months,
having any of the pioglitazone contraindications, hormone
replacement therapy, alcohol or drug abuse, pregnancy and
lactation.
2.3. Efficacy and Safety Assessments. At first visit after rand-
omization, anthropometric variables were measured accord-
ing to standard methods by a trained nurse by means of a
calibrated scale and an anthropometer. Waist circumference
was measured in the standing position, midway between
the lowest rib and iliac crest with a flexible anthropometric
tape. Blood pressure was measured in the right arm at
sitting position after a 10-minute rest using a standard
mercury sphygmomanometer. The body mass index (BMI)
was calculated using the formula: weight (kg)/height2 (m2).
A structured questionnaire containing demographic data
was also filled for all participants. Clinical interview and
examination were done by a single trained physician at
baseline and endpoint. All patients were encouraged to follow
American Heart Association step 1 diet and to exercise
regularly throughout the study. A blood sample was also
obtained from each patient after at least 12 hours of fasting.
Patients were followed by a telephone-based interview
at weeks 6 and 18 after starting of intervention performed
by a physician. These observations were aimed to assess
patients’ adherence to medication as well as to screen for side
effects. In the middle of the intervention period (week 12), all
patients were visited in order to perform a general physical
examination and assessment of liver transaminases. At study
end, similar clinical, anthropometric, and laboratory vari-
ables to the baseline were measured. All telephone-based and
face-to-face interviews were done using a preprepared check
list which was designed to find any plausible side effect of
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pioglitazone, specially the congestive heart failure, with high
sensitivity. If the occurred side effects were not indications
for withdrawal, the administered drug was downtitrated to a
minimumdose of 15mg/day.Our interviewerwas continually
making sure that all women of childbearing potential were
using an approved method of birth control throughout the
study.
2.4. Laboratory Assays. Blood specimens were obtained at
baseline and endpoint after at least 12 hours of overnight
fasting. The venous blood samples were placed into tubes
containing ethylene diamine tetraacetic acid and were cen-
trifuged to separate the serum which was used to analyze the
biochemical factors. Awhole blood samplewas also prepared.
Complete blood count (CBC) with differential was done by
Sysmex KX-21N (Japan) counter. Serum total, low-density
and high-density lipoprotein cholesterol (LDL-C and HDL-
C), triglycerides, high-sensitivity C-reactive protein (hs-
CRP), creatinine, alanine transaminase (ALT) and Aspartate
Transaminase (AST) levels were measured by Hitachi 902
autoanalyzer (Japan) using Pars Azmoon (Iran) analytical
kits. Serum fasting glucose measurement was done using the
same machine and Biosystem (France) kits. Serum insulin
levels were assayed by enzyme-linked immunosorbent assay
(ELISA) method using Monobind kits (CA, USA). Insulin
sensitivity in the fasting state was assessed with homeosta-
sis model assessment (HOMA) and calculated using the
formula: fasting plasma glucose (milligrams per deciliter)
× fasting serum insulin (microunits per milliliter)/405, as
originally described by Matthews et al. [30]. A commercially
available ELISA kit (DLD Diagnostika GmbH, Hamburg,
Germany) was used to measure the serum levels of ADMA.
Serum samples for ADMA assessment were stored at −70∘C
until assay.
All themeasurements were carried out in Isfahan Cardio-
vascular Research Institute laboratory which is qualitatively
controlled by the National Reference Lab of Iran (Tehran,
Iran) and INSTAND e.V. Laboratory (Du¨sseldorf-Germany).
2.5. Statistical Analysis. Baseline demographic data are pre-
sented as mean ± SD or number (percent) where appropriate.
All data were assessed for a normal distribution before
analyses. Skewed variables were normalized based on the
Box-Cox transformation technique. As some participants
were omitted from both groups, we conducted the analyses
based on the intention-to-treat principles. We used mixed
models for the analysis of the effects of time and group
on the changes of our primary outcome variable (serum
ADMA) using the STATA software (Stata/IC 9.2, StataCorp
LP, TX, USA). Models were adjusted for age, sex, and
all components of the MetS. Missing data were replaced
by multi-imputation method using the R software (v2.9.0).
Differences between baseline and posttreatment values of
other variables and ADMA were analyzed using the paired
Student’s 𝑡-test. Comparisons between groups were made
using the independent 𝑡-test for continuous and Chi-square
test for discrete variables. Correlation between changes of
various parameters and ADMA and CRP was studied using
the Pearson correlation test. The Fisher exact test was used to
evaluate the significance of difference in rate of side effects
between intervention and placebo groups. The Statistical
Package for Social Sciences software version 15.0 (SPSS Inc.,
Chicago, IL, USA) was used. A 2-tailed 𝑃 value of ≤0.05 was
considered statistically significant in all of the analyses.
3. Results
From 145 patients screened, 104 (57% female; age between
20 and 70) were eligible and enrolled to the study. After
randomized allocation, 53 patients were assigned to receive
pioglitazone and 51 patients to receive placebo. Study flow
diagram, which is presented in Figure 1, shows how the
participants were selected and why were excluded. At the end
of study, 11 patients of pioglitazone group were no longer
qualified as having metabolic syndrome, compared with 7
participants receiving placebo.
3.1. Baseline Characteristics. Baseline characteristics of two
study groups are summarized in Table 1. As shown, none
of the variables were significantly different among groups
before starting the intervention. Furthermore, the two groups
showed similar concomitant use of various classes of anti-
hypertensive, lipid-lowering, and weight-lowering agents at
baseline and during the intervention period (data are not
shown).
3.2. Changes in Anthropometric Variables and Blood Pressure.
After 24 weeks of receiving pioglitazone, our patients had
experienced a significantly higher increase of BMI versus
placebo-receiving patients (𝑃 = 0.015). Pioglitazone and
placebo-assigned groups have shown a similar significant
decrease in waist circumference (−0.73% versus−1.86% resp.)
and waist-to-hip ratio (−4.30% versus −4.35%, resp.), but the
between-group differences never reached a significant level
(Table 2).
As shown in Table 2, patients of the pioglitazone and
placebo groups experienced a considerable but comparable
drop in systolic (𝑃 < 0.001) and diastolic (𝑃 = 0.002 and
𝑃 = 0.005, resp.) blood pressures.
3.3. Changes in Lipid Profile. After 24 weeks of interven-
tion, the most considerable change was observed in the
plasma level of HDL-C. In contrast with a nonsignificant
decrease in placebo-receiving patients, HDL-Cwas increased
significantly in intervention group (+6.81%; 𝑃 = 0.03) and
changed differently among the two groups (𝑃 = 0.048).
Otherwise, no considerable changes were observed regarding
the plasma levels of total cholesterol as well as LDL-C in
either of our study groups. Similarly, experienced decreases of
triglycerides in both groups comparedwith the baseline levels
never reached our supposed level of significance (−15.85%
versus −7.10%; 𝑃 = 0.414) (Table 2).
3.4. Changes in Insulin Resistance. Although fasting glucose
remained unchanged in both study groups, fasting serum
insulin was decreased significantly in pioglitazone group
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Assessed for eligibility:
clinical examination;
screening laboratory tests
(𝑛 = 145) Excluded (𝑛 = 41)
Received pioglitazone (𝑛 = 53) Received placebo (𝑛 = 51)
Week 1: clinical examination; laboratory tests
Discontinued intervention (𝑛 = 1)
Discontinued intervention (𝑛 = 1)
Discontinued intervention (𝑛 = 9)
Discontinued intervention (𝑛 = 2)
Discontinued intervention (𝑛 = 2)
Discontinued intervention (𝑛 = 2)Discontinued intervention (𝑛 = 2)
Week 6: telephone-based interview
Week 18: telephone-based interview
Week 12: clinical examination; LFTs assessment
Week 24: clinical examination; laboratory tests
Analyzed (𝑛 = 40) Analyzed (𝑛 = 45)
∙ Withdrew consent
∙ Withdrew consent
∙ Withdrew consent
∙ Side effects (𝑛 = 1)
∙ Intended to get pregnant (𝑛 = 1)
∙ Critical medical condition (𝑛 = 1)
∙ Withdrew consent (𝑛 = 1)
∙ Side effects
∙ Side effects (𝑛 = 7)
∙ Critical medical condition (𝑛 = 1)
∙ Emigration (𝑛 = 1)
(𝑛 = 35)
∙ Refused to participate (𝑛 = 6)
∙ Did not meet inclusion criteria
Randomized (𝑛 = 104)
Figure 1: Study flow diagram.
(−34.01%; 𝑃 = 0.003) and nonsignificantly in placebo group
(−10.26%; 𝑃 = 0.196), which did not reach a pronounced
between-group difference (𝑃 = 0.137) (Table 2).
Based on our findings, pioglitazone induced a consid-
erable decline in the degree of IR as estimated by HOMA-
IR index in our patients. We have recorded a remarkable
decrease of 38.96% compared with the baseline values in
HOMA-IR index at the endpoint in pioglitazone-receiving
patients (𝑃 = 0.003). Nevertheless, between-group differ-
ences of changes were not significant (Table 2).
3.5. Changes in Markers of Inflammation and Endothelial
Function. In our study, pioglitazone-receiving patients expe-
rienced a considerable decrease of 33.44% in the serum level
of CRP (𝑃 = 0.030), while those who received placebo have
shown amodest increase of 4.87%whichwas significantly dif-
ferent (𝑃 = 0.040) (Table 2). Changes of CRP level correlated
with the changes of neither HOMA-IR index nor fasting
insulin (𝑟 = 0.250, 𝑃 = 0.130 and 𝑟 = 0.205, 𝑃 = 0.218,
resp.), indicating an independent effect. Mean peripheral
WBC count was decreased in pioglitazone group (𝑃 = 0.038)
but not differently from the placebo-assigned patients.
In our study, pioglitazone has failed to change the serum
level of ADMA significantly in either of two study groups, as
determined by bivariate analyses (Table 2). Similarly, none of
the crude (Time: 𝑍 = 0.80, 𝑃 = 0.42; Group: 𝑍 = −0.82, 𝑃 =
0.41) and adjusted models for age, sex, and components of
MetS (Time:𝑍 = 0.78,𝑃 = 0.44; Group:𝑍 = −0.76,𝑃 = 0.45)
was successful in finding a significant effect of either time or
group on serum levels of ADMA.
3.6. Safety and Tolerability. Experienced new-onset or
aggravated signs and symptoms in pioglitazone and placebo
groups are shown in Figure 2. None of the reported
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Table 1: Baseline characteristics of participantsa,b.
Pioglitazone
(𝑛 = 53)
Placebo
(𝑛 = 51) P value
Male sex 19 (35.8%) 25 (49.0%) 0.306
Age (years) 49.8 ± 10.05 50.9 ± 10.11 0.599
Education 0.442
Undergraduate 46 (86.8%) 44 (83.3%)
Graduate 7 (13.2%) 7 (13.7%)
Current smokerc 10 (18.9%) 4 (7.8%) 0.108
Body mass index
(kg/m2) 30.26 ± 3.23 30.06 ± 4.20 0.809
Waist circumference
(cm) 102.72 ± 9.26 101.74 ± 10.18 0.652
Waist-to-hip ratio 0.97 ± 0.07 0.96 ± 0.07 0.656
Blood pressure
(mmHg)
Systolic 129.22 ± 14.87 134.23 ± 21.14 0.262
Diastolic 82.50 ± 8.33 85.64 ± 10.21 0.166
Fasting glucose
(mg/dL) 94.10 ± 11.17 95.12 ± 11.20 0.106
Serum lipids (mg/dL)
Total cholesterol 204.65 ± 31.10 215.80 ± 40.41 0.184
HDL-C 42.00 ± 10.52 43.05 ± 8.68 0.631
LDL-C 110.18 ± 19.60 118.15 ± 29.54 0.185
Triglycerides 226.54 ± 145.53 202.97 ± 108.41 0.429
Liver transaminases
(U/L)
ALT 29.97 ± 12.99 26.53 ± 12.09 0.232
AST 26.92 ± 6.28 25.25 ± 6.16 0.247
White blood cells
(103/mL) 6.25 ± 1.40 6.58 ± 1.36 0.396
hs-CRP (mg/L) 3.14 ± 2.03 2.26 ± 1.25 0.070
Fasting insulin
(𝜇U/mL) 13.24 ± 5.74 13.43 ± 7.96 0.913
HOMA-IR index 3.21 ± 1.38 3.18 ± 2.05 0.937
ADMA (𝜇m/L) 0.64 ± 0.36 0.70 ± 0.40 0.652
aData are expressed as mean ± SD for continuous variables and number
(percentage) of participants for categorical variables.
bAbbreviations are defined in the text.
cWas defined as one who regularly smoked at least one cigarette per day.
complications were statistically different between two
groups.
As shown in Figure 1, eight patients from the pioglitazone
group and one patient from the placebo group were excluded
from the study because of the side effects. One of the
pioglitazone-receiving participants was shown a rise of more
than 2.5 times of the upper limit of normal in ALT after 3
months and was excluded from the study. On the average,
serumALT levels were significantly decreased in pioglitazone
group (𝑃 = 0.015) and increased in placebo group (𝑃 =
0.026) (Table 2). In contrast, AST levels only decreased in
the pioglitazone-assigned patients (𝑃 ≤ 0.001). Of note,
the recoded values of liver transaminases in the middle of
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Figure 2: Number of participants with new-onset or aggravated
signs and symptoms recorded during the follow-up period.
the follow-up period were only for screening purposes and
are not reported.
4. Discussion
The present study was a randomized placebo-controlled trial
designed to assess the efficacy of pioglitazone in improving
a number of vasoreactivity, inflammatory, and metabolic
biomarkers.
We assessed the changes in serum levels of ADMA
after 24 weeks of pioglitazone administration. Contrary to
our primary hypothesis, we could not find any significant
alteration in this measure. Supporting data has been obtained
through a number of animal [25], in vitro, and clinical studies.
Albsmeier showed that neither agonists nor antagonists of
PPAR-𝛾 had significant effect on cellular ADMA liberation
[23]. Similarly, in a 6-month active-control trial, rosiglitazone
plus metformin failed to decrease ADMA levels in diabetic
patients [15]. Here a great deal of controversy emerges when
the following refuting pieces of evidence are taken into
consideration. TZDs were effective in reducing urine and
plasma levels of ADMA in an animal study [24] and two
small uncontrolled clinical trials [17, 26]. But themost reliable
contradictory evidence of our results to datewas derived from
an 8-week rosiglitazone trial performed on 70 nondiabetic
MetS patients [14]. However, the results of the present study
further fueled the existing controversy rather than helping to
resolve it.
Presently, there is a little doubt about the contribution
of chronic subclinical inflammation in the pathophysiol-
ogy of IR and MetS [31]. Moreover, it has been indicated
that elevated level of CRP, as one of the most sensitive
measures of inflammation, has a predictive value for the
development of T2DM as well as the risk of future car-
diovascular events [32]. Agonists of PPAR-𝛾 have shown
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a wide range of anti-inflammatory properties in different
clinical settings irrespective of changes in insulin sensitivity
[33]. The independent CRP-lowering effect of pioglitazone
shown in this study is in agreement with the findings of
an absolute majority of previous investigations in diabetic
and nondiabetic individuals [32]. The hypothesis that this
property implicates in the reducing effect of pioglitazone on
cardiac and noncardiac mortality rate [34] is waiting to be
tested by future studies.
Influences of TZDs on lipid metabolism in diabetic
patients have widely been investigated. Results of a meta-
analysis of 23 randomized clinical trials have shown an
improving effect of pioglitazone on serum triglycerides and
HDL-C [35]. Nonetheless, handful number of available trials
in nondiabetic insulin-resistant patients has not produced
consistent results. Our study, the largest so far in terms of
the sample size, in line with three other trials [10, 12, 36] has
found pioglitazone to have a significant increasing effect on
serum HDL-C but not on triglycerides. In contrast, others
[37–39] have failed to observe any considerable change in
lipid profile of nondiabetic participants after 12–16 weeks
of pioglitazone administration. While these results await
future confirmation, the null effect of pioglitazone on total
cholesterol and LDL-C in our study seems undisputed as no
contradictory reports have been found.
We have observed a significantly higher increase in BMI
in pioglitazone-treated patients. The recorded mean increase
of 2.73 kg in our patients was within the previously reported
range of weight gain induced by TZD compounds in diabetic
patients (from 2.0 to 4.3 kg) [40]. However, results in non-
diabetic individuals have been mixed as some smaller-sized
trials failed to document a significant effect of pioglitazone
on body weight [12, 36, 38]. Fluid retention, differentiation
of adipocytes, increased body fat, and increased appetite are
among mechanisms which were supposed to be responsible
for the weight gain in TZD users [41].
Surprisingly, the indices of central adiposity and blood
pressure were diminished similarly in our both study groups.
The authors suppose that this finding could be the conse-
quence of sustained blood pressure management and lifestyle
modification advice given to the participants throughout
the follow-up period, and it could not be attributed to the
interventions.
As expected, pioglitazone has caused a significant impro-
vement in surrogate indicators of insulin sensitivity irrelevant
of its effects on fasting glucose level. But the HOMA-IR
index and fasting serum insulin were also decreased in
our placebo group to a nonsignificant but enough degree
to prevent the between-group difference of changes from
reaching a significant level. We suppose that this finding
could be interpreted by the observed decline in our patients’
waist circumference. Considering the fact that waist circum-
ference is linearly related to IR [42] and reduction of this
measure of visceral adiposity could lead to an improvement in
insulin sensitivity [43].These outcomes highlight the efficacy
of lifestyle modification advice in improving IR in MetS
patients.
The present study has evidenced the beneficial effects of
pioglitazone on both ALT and AST levels in non-diabetic
MetS patients. This effect is considerable as ALT has dis-
played an inverse relationship with cardiovascular and non-
cardiovascular events in population-based studies [44]. Clar-
ification of the mechanisms needs more detailed studies.
Overall, our trial was not powered to reliably investigate
the medication’s safety. Accordingly and with regard to the
paucity of papers reporting the side effect profile of TZDs
in non-diabetic insulin-resistant patients, making definite
statements is impossible at the present stage.
In spite of benefiting from being randomized, controlled,
and having a proper duration of intervention, the validity
of our results is affected by some limitations. First is the
fact that we used a static index to estimate IR rather than
a better-validated direct measure such as hyperinsuline-
mic euglycemic glucose clamp. Additionally, it seems that
repeated measurement of the metabolic biomarkers would
provide the possibility of extracting pathophysiologic clues
from the trend of induced changes, which was not performed
in this study. Finally, the design of this study would have been
more favorable if direct measures of endothelial function had
been used concomitantly with the biomarkers.
Considering our findings, pioglitazone had positive
effects on insulin sensitivity, lipid profile, liver transaminases,
and systemic inflammation, despite inducing an increase in
BMI and failure inmaking a significant change in serum level
of ADMA. In conclusion, this study has added to the priory
obtained evidence that pioglitazone could be considered in
non-diabetic MetS patients with preserved cardiac function
who failed to follow the life style modification recommenda-
tions.
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